Rapidly developing pulmonary fibrosis associated with the use of the anti-cancer drug oxaliplatin has been
reported mainly by Asiatic literature as isolate case reports. This rare but potentially fatal side effect has neither identified
risk factors nor established treatment guideline. We report here a new clinical case concerning a patient with advanced
gastric cancer treated with the oxaliplatin-based FOLFOX regimen along with a review of the literature as well as a
discussion of emerging experimental treatment mainly based on imatinib.
Keywords: Imatinib, oxaliplatin, pulmonary fibrosis.
Rights & PermissionsPrintExport